Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06174766
PHASE3

A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

Sponsor: Hanmi Pharmaceutical Company Limited

View on ClinicalTrials.gov

Summary

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension

Official title: A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HGP2102 in Patients With Essential Hypertension

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

324

Start Date

2024-05-10

Completion Date

2026-12-31

Last Updated

2025-06-12

Healthy Volunteers

No

Conditions

Interventions

DRUG

HGP2102-1

Test drug

DRUG

HGP2102-2

Test drug

DRUG

RLD2209-1

Control drug

DRUG

RLD2209-2

Control drug

Locations (1)

Sevrance hosptal

Seodaemun-gu, Seoul, South Korea